S62
Brachytherapy - Gynaecology
ESTRO 2026
had local along with systemic relapse, and 5 had distant recurrence. The 2-year local control was 88.9% and the 2-year disease-free survival rate was 74.2%. The crude rate for G2 and G3 late toxicity was 37.9 % and 6.8% respectively, vaginal stenosis was the most common toxicity. Conclusion: Combined intracavitary and interstitial brachytherapy application using the Utrecht applicator in patients with large residual disease after external beam radiotherapy can achieve local control with acceptable toxicity in most cases. The majority of our patients had advanced disease with a median tumor volume of 117 cm3, baseline hydroureteronephrosis, and myometrial invasion. MRI-based target volume delineation could further escalate the dose and may lead to even better outcomes. Keywords: cervical cancer, hybrid applicator References: 1. Serban M, Kirisits C, de Leeuw A, Pötter R et al. Ring Versus Ovoids and Intracavitary Versus Intracavitary- Interstitial Applicators in Cervical Cancer Brachytherapy: Results from the EMBRACE I Study. Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):1052- 1062. 2. Nomden CN, de Leeuw AA et al. Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1424-30.3. Paul Rogowski, Maya Rottler, Franziska Walter et al. Clinical outcome of combined intracavitary/interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer. Gynecologic Oncology. 2022 Sep;166(4): 576- 581 Digital Poster 2291 Radio-chemotherapy and interventional radiotherapy (modern brachitherapy) in vaginal carcinoma: a monocentric experience Valentina Lancellotta 1 , Gabriella Macchia 2 , Maria Concetta La Milia 1 , Giorgia Garganese 3 , Bruno Fionda 1 , Martina De Angeli 1 , Enrico Rosa 1 , Donato Pezzulla 2 , Benedetta Gui 1 , Luca Russo 1 , Simona Maria Fragomeni 3 , Rosa Autorino 1 , Maria Antonietta Gambacorta 1 , Luca Tagliaferri 1 1 Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC Radioterapia Oncologica, Rome, Italy. 2 Radiation Oncology Unit, Responsible Research Hospital, Radiation Oncology Unit, Università Cattolica del Sacro Cuore, Campobasso, Italy. 3 UOC Ginecologia Oncologica, Dipartimento Scienze della salute della donna, del bambino e di sanità pubblica, Fondazione
fraction along with weekly Cisplatin chemotherapy (40mg/m 2). Dosimetry, 2-year local control, and toxicity were assessed. Results:
The median age of the population was 56 years, with a range of 42 to 68 years. The median HRCTV D98% was 74.1 83.7Gy Gy (EQD2 10), the median HRCTV D90% was 83.7Gy Gy (EQD2 10), the median D2cc was 72Gy Gy (EQD2 3) for rectum, 88.4Gy(EQD2 3) for bladder, and 64.3Gy(EQD2 3) for sigmoid.With a median follow- up of 49 months, 8 patients experienced disease recurrence, 1 patient had isolated local recurrence, 2
Made with FlippingBook - Share PDF online